슬롯사이트 볼트 expands autoimmune disease treatment bidding in Italy, maintains No. 1 spot in prescriptions

[by Kang, In Hyo] 슬롯사이트 볼트 announced on March 20 its expansion of bidding performance in Italy, one of the five key European countries, with a strategic emphasis on autoimmune disease treatments.

In just two months since its launch in January of this year, ‘Steqeyma (ustekinumab)’ paved the way by securing its bidding performance. 슬롯사이트 볼트’s Italian subsidiary successfully won the bid for ‘ustekinumab’ in four regions: Piemonte, Valle d’Aosta, Liguria, and Sardegna. Together, these regions account for approximately 10% of the Italian ustekinumab market, with Steqeyma expected to be supplied through 2028.

Additionally, the ‘adalimumab’ bid conducted in Lazio, Lombardia, and Umbria, key regions among 슬롯사이트 볼트’s 21 states, ‘Yuflyma (adalimumab)’ was successfully awarded. Starting this month, Yuflyma will be supplied to Lazio and Lombardia for the next three years and to Umbria for the next two years.

According to IQVIA, a pharmaceutical market research institute, Yuflyma held a 43% market share in 슬롯사이트 볼트 during Q3 2024, maintaining its top spot in prescriptions from the previous quarter. In particular, its market share increased by 5 percentage points in the same quarter, further widening the gap with competing products. If this order performance is reflected, Yuflyma is expected to further solidify its dominant position as the leading prescription treatment.

Order performance is also continuing for the ‘Remsima product line (infliximab, IV·SC),’ 슬롯사이트 볼트’s flagship product portfolio. ‘Remsima,’ which has become the first global blockbuster drug in Korea, recently secured the bid in the Umbria region and is scheduled to be supplied for the next two years, until 2027.

‘Remsima SC’, the world’s only subcutaneous injection (SC) formulation of infliximab, is now available for bidding in all Italian regions, as the Sardegna region, previously the only region in 슬롯사이트 볼트 without a bidding market for infliximab SC, has newly established the market. As the sole ‘infliximab SC’ formulation product in the world, Remsima SC faces virtually no competition, and stable sales are expected through this newly secured market.

The order performance of the Remsima product line is translating into actual prescription growth. As of the third quarter of 2024, the combined market share of Remsima IV and SC in 슬롯사이트 볼트 reached 56%, maintaining the top position for three consecutive quarters. Remsima SC alone captured a market share of 21%, continuing its growth each quarter.

The excellent performance of 슬롯사이트 볼트 Italy in the bidding competition can be attributed to its ‘customized direct sales strategy.’ Beginning with Remsima in 2020, 슬롯사이트 볼트 transitioned to direct sales for all its products in Italy, focusing on building a network with influential bidding agencies in the local pharmaceutical market. The company explains that this approach has enabled it to expand its performance by emphasizing product competitiveness and supply stability, while also minimizing the time from winning the bid to the actual supply of medicines. This strategy has helped enhance the reliability of its products and the trust in the company.

“Since switching to direct sales in 2020, we have consistently won bids in each state government tender, and as a result, 슬롯사이트 볼트’s autoimmune disease treatments, including the Remsima product line and Yuflyma, have maintained the top spot in prescriptions, outpacing competitors,” expressed Won-sik (Daniel) Yoo, General Manager of 슬롯사이트 볼트 Healthcare Italy. “Stekeyma, launched in January of this year, has also quickly secured bids and is making its way into the market. As another autoimmune disease treatment, we will continue more aggressive sales efforts to become the leader in prescriptions, leveraging the same human and physical networks as our existing products,” he added.